Gbor J Tigyi

List of Publications by Year in Descending Order

173 papers	8,974 citations	53 h-index	88 g-index
181 ext. papers	9,604 ext. citations	5.6 avg, IF	5.63 L-index

#	Paper	IF	Citations
173	Evaluation of In-cage Filter Paper as a Replacement for Sentinel Mice in the Detection of Murine Pathogens. *Journal of the American Association for Laboratory Animal Science*, **2021**, 60, 160-167	1.3	3
172	EIF5A2 controls ovarian tumor growth and metastasis by promoting epithelial to mesenchymal transition via the TGF□pathway. *Cell and Bioscience*, **2021**, 11, 70	9.8	5
171	Revisiting the role of lysophosphatidic acid in stem cell biology. *Experimental Biology and Medicine*, **2021**, 246, 1802-1809	3.7	1
170	Dysregulation of lysophospholipid signaling by p53 in malignant cells and the tumor microenvironment. *Cellular Signalling*, **2021**, 78, 109850	4.9	3
169	Phospholipids | Lysophospholipid Receptors **2021**, 545-551		
168	A Luminacin D Analog HL142 Inhibits Ovarian Tumor Growth and Metastasis by Reversing EMT and Attenuating the TGF□and FAK Pathways. *Journal of Cancer*, **2021**, 12, 5654-5663	4.5	1
167	Adipose-Derived Stem Cells Facilitate Ovarian Tumor Growth and Metastasis by Promoting Epithelial to Mesenchymal Transition Through Activating the TGF-□Pathway.. *Frontiers in Oncology*, **2021**, 11, 756011	5.3	2
166	Regulation of Tumor Immunity by Lysophosphatidic Acid. *Cancers*, **2020**, 12,	6.6	14
165	Optical Control of Lysophosphatidic Acid Signaling. *Journal of the American Chemical Society*, **2020**, 142, 10612-10616	16.4	15
164	The role of lysophosphatidic acid receptor 1 in inflammatory response induced by lipopolysaccharide from Porphyromonas gingivalis in human periodontal ligament stem cells. *International Journal of Oral Biology: Official Journal of the Korean Academy of Oral Biology and the UCLA Dental Research Institute*, **2020**, 45, 42-50	0.2	1
163	Molecular modelling guided design, synthesis and QSAR analysis of new small molecule non-lipid autotaxin inhibitors. *Bioorganic Chemistry*, **2020**, 103, 104188	5.1	2
162	Opposing Roles of S1P Receptors in Myocardial Function. *Cells*, **2020**, 9,	7.9	2
161	LPAR2 receptor activation attenuates radiation-induced disruption of apical junctional complexes and mucosal barrier dysfunction in mouse colon. *FASEB Journal*, **2020**, 34, 11641-11657	0.9	5
160	Lysophosphatidic acid type 2 receptor agonists in targeted drug development offer broad therapeutic potential. *Journal of Lipid Research*, **2019**, 60, 464-474	6.3	12
159	Osteoclast-Derived Autotaxin, a Distinguishing Factor for Inflammatory Bone Loss. *Arthritis and Rheumatology*, **2019**, 71, 1801-1811	9.5	7
158	LPA Is an Inhibitory Receptor That Suppresses CD8 T-Cell Cytotoxic Function via Disruption of Early TCR Signaling. *Frontiers in Immunology*, **2019**, 10, 1159	8.4	31
157	Optical control of sphingosine-1-phosphate formation and function. *Nature Chemical Biology*, **2019**, 15, 623-631	11.7	40

156	Sphingosine-1-Phosphate Enhances Adrenergic Vasoconstriction via S1P2-G-ROCK Mediated Signaling. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	3
155	Regulation of tumor cell - Microenvironment interaction by the autotaxin-lysophosphatidic acid receptor axis. *Advances in Biological Regulation*, **2019**, 71, 183-193	6.2	36
154	Role of autotaxin in cancer stem cells. *Cancer and Metastasis Reviews*, **2018**, 37, 509-518	9.6	18
153	The LPA receptor agonist Radioprotectin-1 spares Lgr5-positive intestinal stem cells from radiation injury in murine enteroids. *Cellular Signalling*, **2018**, 51, 23-33	4.9	11
152	Prevention and treatment of secretory diarrhea by the lysophosphatidic acid analog Rx100. *Experimental Biology and Medicine*, **2018**, 243, 1056-1065	3.7	4
151	Highly Potent Non-Carboxylic Acid Autotaxin Inhibitors Reduce Melanoma Metastasis and Chemotherapeutic Resistance of Breast Cancer Stem Cells. *Journal of Medicinal Chemistry*, **2017**, 60, 1309-1324	8.3	36
150	LPA receptor-mediated thromboxane A release is responsible for lysophosphatidic acid-induced vascular smooth muscle contraction. *FASEB Journal*, **2017**, 31, 1547-1555	0.9	14
149	Pharmacological activation of lysophosphatidic acid receptors regulates erythropoiesis. *Scientific Reports*, **2016**, 6, 27050	4.9	17
148	Rapid disruption of intestinal epithelial tight junction and barrier dysfunction by ionizing radiation in mouse colon in vivo: protection by N-acetyl-l-cysteine. *American Journal of Physiology - Renal Physiology*, **2016**, 310, G705-15	5.1	51
147	Novel Inhibitory Effect of a Lysophosphatidic Acid 2 Agonist on Allergen-Driven Airway Inflammation. *American Journal of Respiratory Cell and Molecular Biology*, **2016**, 54, 402-9	5.7	19
146	A reflection of the lasting contributions from Dr. Robert Bittman to sterol trafficking, sphingolipid and phospholipid research. *Progress in Lipid Research*, **2016**, 61, 19-29	14.3	
145	Discovery and synthetic optimization of a novel scaffold for hydrophobic tunnel-targeted autotaxin inhibition. *Bioorganic and Medicinal Chemistry*, **2016**, 24, 4660-4674	3.4	5
144	The autotaxin-LPA2 GPCR axis is modulated by irradiation and facilitates DNA damage repair. *Cellular Signalling*, **2015**, 27, 1751-62	4.9	29
143	Mitigation of the hematopoietic and gastrointestinal acute radiation syndrome by octadecenyl thiophosphate, a small molecule mimic of lysophosphatidic acid. *Radiation Research*, **2015**, 183, 465-75	3.1	24
142	Opposing regulation of megakaryopoiesis by LPA receptors 2 and 3 in K562 human erythroleukemia cells. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2015**, 1851, 172-83	5	8
141	Autotaxin and LPA1 and LPA5 receptors exert disparate functions in tumor cells versus the host tissue microenvironment in melanoma invasion and metastasis. *Molecular Cancer Research*, **2015**, 13, 174-85	6.6	61
140	miR-203 Functions as a Tumor Suppressor by Inhibiting Epithelial to Mesenchymal Transition in Ovarian Cancer. *Journal of Cancer Science & Therapy*, **2015**, 7, 34-43	5	34
139	Sphingosine 1-phosphate is a ligand for peroxisome proliferator-activated receptor- that regulates neoangiogenesis. *FASEB Journal*, **2015**, 29, 3638-53	0.9	49

138	Combined mitigation of the gastrointestinal and hematopoietic acute radiation syndromes by an LPA2 receptor-specific nonlipid agonist. *Chemistry and Biology*, **2015**, 22, 206-16		31
137	Uncovering unique roles of LPA receptors in the tumor microenvironment. *Receptors & Clinical Investigation*, **2015**, 2,		11
136	Lysophosphatidic acid induces vasodilation mediated by LPA1 receptors, phospholipase C, and endothelial nitric oxide synthase. *FASEB Journal*, **2014**, 28, 880-90	0.9	17
135	Design and synthesis of sulfamoyl benzoic acid analogues with subnanomolar agonist activity specific to the LPA2 receptor. *Journal of Medicinal Chemistry*, **2014**, 57, 7136-40	8.3	12
134	Interaction of platelet-derived autotaxin with tumor integrin V□3 controls metastasis of breast cancer cells to bone. *Blood*, **2014**, 124, 3141-50	2.2	108
133	Doxycycline inducible Krüppel-like factor 4 lentiviral vector mediates mesenchymal to epithelial transition in ovarian cancer cells. *PLoS ONE*, **2014**, 9, e105331	3.7	35
132	Asymmetrical macromolecular complex formation of lysophosphatidic acid receptor 2 (LPA2) mediates gradient sensing in fibroblasts. *Journal of Biological Chemistry*, **2014**, 289, 35757-69	5.4	6
131	Lysophosphatidic acid receptor 5 inhibits B cell antigen receptor signaling and antibody response. *Journal of Immunology*, **2014**, 193, 85-95	5.3	25
130	Targeting the hydrophobic pocket of autotaxin with virtual screening of inhibitors identifies a common aromatic sulfonamide structural motif. *FEBS Journal*, **2014**, 281, 1017-28	5.7	17
129	Structural determinants of the transient receptor potential 1 (TRPV1) channel activation by phospholipid analogs. *Journal of Biological Chemistry*, **2014**, 289, 24079-90	5.4	24
128	Regulation of the Nuclear Hormone Receptor Ppar□by Endogenous Lysophosphatidic Acids (LPAS) **2013**, 349-372		
127	Role of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2013**, 1831, 74-85	5	90
126	Mitigation of radiation injury by selective stimulation of the LPA(2) receptor. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2013**, 1831, 117-25	5	22
125	Integrating the puzzle pieces: the current atomistic picture of phospholipid-G protein coupled receptor interactions. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2013**, 1831, 2-12	5	16
124	The transcription factor CREB enhances interleukin-17A production and inflammation in a mouse model of atherosclerosis. *Science Signaling*, **2013**, 6, ra83	8.8	45
123	Lysophosphatidic acid inhibits CD8 T cell activation and control of tumor progression. *Cancer Immunology Research*, **2013**, 1, 245-55	12.5	52
122	Hits of a high-throughput screen identify the hydrophobic pocket of autotaxin/lysophospholipase D as an inhibitory surface. *Molecular Pharmacology*, **2013**, 84, 415-24	4.3	29
121	Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis. *Biochemical Society Transactions*, **2012**, 40, 31-6	5.1	68

120	High-throughput assays to measure intracellular Ca□+ mobilization in cells that express recombinant S1P receptor subtypes. *Methods in Molecular Biology*, **2012**, 874, 77-87	1.4	3
119	Virtual screening for LPA2-specific agonists identifies a nonlipid compound with antiapoptotic actions. *Molecular Pharmacology*, **2012**, 82, 1162-73	4.3	42
118	DiGeorge syndrome critical region 8 (DGCR8) protein-mediated microRNA biogenesis is essential for vascular smooth muscle cell development in mice. *Journal of Biological Chemistry*, **2012**, 287, 19018-28	5.4	43
117	Mechanisms of Radiomitigative Cell Signaling Via Lysophosphatidic Acid Receptors. *FASEB Journal*, **2012**, 26, 993.4	0.9	
116	Conditional deletion of Dicer in vascular smooth muscle cells leads to the developmental delay and embryonic mortality. *Biochemical and Biophysical Research Communications*, **2011**, 408, 369-74	3.4	41
115	Location, location, location: a crystal-clear view of autotaxin saturating LPA receptors. *Nature Structural and Molecular Biology*, **2011**, 18, 117-8	17.6	19
114	Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic activity. *ChemMedChem*, **2011**, 6, 922-35	3.7	49
113	The phospholipase A1 activity of lysophospholipase A-I links platelet activation to LPA production during blood coagulation. *Journal of Lipid Research*, **2011**, 52, 958-70	6.3	41
112	FTY720 (Gilenya) phosphate selectivity of sphingosine 1-phosphate receptor subtype 1 (S1P1) G protein-coupled receptor requires motifs in intracellular loop 1 and transmembrane domain 2. *Journal of Biological Chemistry*, **2011**, 286, 30513-30525	5.4	15
111	Aiming drug discovery at lysophosphatidic acid targets. *British Journal of Pharmacology*, **2010**, 161, 241-70	8.6	131
110	Sphingosine 1-phosphate receptor 4 uses HER2 (ERBB2) to regulate extracellular signal regulated kinase-1/2 in MDA-MB-453 breast cancer cells. *Journal of Biological Chemistry*, **2010**, 285, 35957-66	5.4	64
109	Phospholipase D2-dependent inhibition of the nuclear hormone receptor PPARgamma by cyclic phosphatidic acid. *Molecular Cell*, **2010**, 39, 421-32	17.6	100
108	Transcellular Invasion of MM1 Rat Ascites Hepatoma Cells Requires Matrix Metalloproteinases Derived from Host Mesothelium. *Cytologia*, **2010**, 75, 267-272	0.9	
107	Cdc42/N-WASP and Rac1/WAVE2 Required for LPA-induced Migration of Rat Ascites Hepatoma Cells. *Cytologia*, **2010**, 75, 195-201	0.9	
106	Conservation of miR-15a/16-1 and miR-15b/16-2 clusters. *Mammalian Genome*, **2010**, 21, 88-94	3.2	63
105	Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells. *Cellular Signalling*, **2010**, 22, 926-35	4.9	57
104	FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells. *Cellular Signalling*, **2010**, 22, 1536-42	4.9	156
103	(S)-FTY720-vinylphosphonate, an analogue of the immunosuppressive agent FTY720, is a pan-antagonist of sphingosine 1-phosphate GPCR signaling and inhibits autotaxin activity. *Cellular Signalling*, **2010**, 22, 1543-53	4.9	48

102	Development of an LC-MS/MS assay to determine plasma pharmacokinetics of the radioprotectant octadecenyl thiophosphate (OTP) in monkeys. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2010**, 878, 2379-83	3.2	8
101	2D binary QSAR modeling of LPA3 receptor antagonism. *Journal of Molecular Graphics and Modelling*, **2010**, 28, 828-33	2.8	6
100	Synthesis and pharmacological evaluation of the stereoisomers of 3-carba cyclic-phosphatidic acid. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 7525-8	2.9	19
99	FTY720 S-ene-phosphonate is a novel pan-antagonist of the S1P receptors that inhibits lymphocyte egress. *FASEB Journal*, **2010**, 24, lb100	0.9	2
98	Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation. *Journal of Biological Chemistry*, **2009**, 284, 17304-17319	5.4	110
97	Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. *Cancer Research*, **2009**, 69, 5441-9	10.1	139
96	Lysophosphatidic acid 2 receptor-mediated supramolecular complex formation regulates its antiapoptotic effect. *Journal of Biological Chemistry*, **2009**, 284, 14558-71	5.4	57
95	Lysophosphatidic acid-induced arterial wall remodeling: requirement of PPARgamma but not LPA1 or LPA2 GPCR. *Cellular Signalling*, **2009**, 21, 1874-84	4.9	34
94	Structure-based drug design identifies novel LPA3 antagonists. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 7457-64	3.4	23
93	Chiral vinylphosphonate and phosphonate analogues of the immunosuppressive agent FTY720. *Journal of Organic Chemistry*, **2009**, 74, 3192-5	4.2	40
92	Autotaxin and lysophosphatidic acid stimulate intestinal cell motility by redistribution of the actin modifying protein villin to the developing lamellipodia. *Experimental Cell Research*, **2008**, 314, 530-42	4.2	30
91	Lysophosphatidic acid (LPA)-induced vasodilator-stimulated phosphoprotein mediates lamellipodia formation to initiate motility in PC-3 prostate cancer cells. *Molecular Oncology*, **2008**, 2, 54-69	7.9	27
90	Lysophospholipid signaling: beyond the EDGs. *Biochimica Et Biophysica Acta - General Subjects*, **2008** , 1780, 597-605	4	22
89	The early- and late stages in phenotypic modulation of vascular smooth muscle cells: differential roles for lysophosphatidic acid. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2008**, 1781, 571-81	5	14
88	Synthesis, pharmacology, and cell biology of sn-2-aminooxy analogues of lysophosphatidic acid. *Organic Letters*, **2008**, 10, 1111-4	6.2	14
87	Subtype-specific residues involved in ligand activation of the endothelial differentiation gene family lysophosphatidic acid receptors. *Journal of Biological Chemistry*, **2008**, 283, 12175-87	5.4	30
86	Identification of non-lipid LPA3 antagonists by virtual screening. *Bioorganic and Medicinal Chemistry* , **2008**, 16, 6207-17	3.4	25
85	The lysophosphatidic acid type 2 receptor is required for protection against radiation-induced intestinal injury. *Gastroenterology*, **2007**, 132, 1834-51	13.3	93

84	Alpha-substituted phosphonate analogues of lysophosphatidic acid (LPA) selectively inhibit production and action of LPA. *ChemMedChem*, **2007**, 2, 679-90	3.7	79
83	Alkoxymethylenephosphonate analogues of (Lyso) phosphatidic acid stimulate signaling networks coupled to the LPA2 receptor. *ChemMedChem*, **2007**, 2, 1789-98	3.7	10
82	Sphingosine 1-phosphate pKa and binding constants: intramolecular and intermolecular influences. *Journal of Molecular Graphics and Modelling*, **2007**, 26, 519-28	2.8	18
81	Receptor tyrosine kinase-G-protein coupled receptor complex signaling in mammalian cells. *Advances in Enzyme Regulation*, **2007**, 47, 271-80		24
80	Identification of the hydrophobic ligand binding pocket of the S1P1 receptor. *Journal of Biological Chemistry*, **2007**, 282, 2374-85	5.4	41
79	The lysophosphatidic acid 2 receptor mediates down-regulation of Siva-1 to promote cell survival. *Journal of Biological Chemistry*, **2007**, 282, 37759-69	5.4	52
78	Inhibition of transcellular tumor cell migration and metastasis by novel carba-derivatives of cyclic phosphatidic acid. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2007**, 1771, 103-12	5	47
77	Identification of Darmstoff analogs as selective agonists and antagonists of lysophosphatidic acid receptors. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 451-6	2.9	35
76	Serine phosphorylation differentially affects RhoA binding to effectors: implications to NGF-induced neurite outgrowth. *Cellular Signalling*, **2006**, 18, 704-14	4.9	45
75	The functional PDGFbeta receptor-S1P1 receptor signaling complex is involved in regulating migration of mouse embryonic fibroblasts in response to platelet derived growth factor. *Prostaglandins and Other Lipid Mediators*, **2006**, 80, 74-80	3.7	28
74	MicroRNA trafficking and human cancer. *Cancer Biology and Therapy*, **2006**, 5, 573-8	4.6	32
73	Different residues mediate recognition of 1-O-oleyllysophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor gamma. *Journal of Biological Chemistry*, **2006**, 281, 3398-407	5.4	71
72	Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis. *Journal of Biological Chemistry*, **2006**, 281, 22786-93	5.4	125
71	Cell migration activated by platelet-derived growth factor receptor is blocked by an inverse agonist of the sphingosine 1-phosphate receptor-1. *FASEB Journal*, **2006**, 20, 509-11	0.9	76
70	Lipid phosphate phosphatase-1 regulates lysophosphatidate-induced fibroblast migration by controlling phospholipase D2-dependent phosphatidate generation. *Journal of Biological Chemistry* , **2006**, 281, 38418-29	5.4	51
69	Phosphonothioate and fluoromethylene phosphonate analogues of cyclic phosphatidic acid: Novel antagonists of lysophosphatidic acid receptors. *Journal of Medicinal Chemistry*, **2006**, 49, 5309-15	8.3	32
68	Synthesis of photoactivatable analogues of lysophosphatidic acid and covalent labeling of plasma proteins. *Journal of Organic Chemistry*, **2006**, 71, 629-35	4.2	12
67	Synthesis of cyclic phosphonate analogues of (lyso)phosphatidic acid using a ring-closing metathesis reaction. *Journal of Organic Chemistry*, **2006**, 71, 6061-6	4.2	21

66	Farnesyl phosphates are endogenous ligands of lysophosphatidic acid receptors: inhibition of LPA GPCR and activation of PPARs. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2006**, 1761, 1506-14	5	22
65	Protean agonism of the lysophosphatidic acid receptor-1 with Ki16425 reduces nerve growth factor-induced neurite outgrowth in pheochromocytoma 12 cells. *Journal of Neurochemistry*, **2006**, 98, 1920-9	6	21
64	Synthesis and pharmacological evaluation of second-generation phosphatidic acid derivatives as lysophosphatidic acid receptor ligands. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 633-40	2.9	45
63	Lysophosphatidic acid receptor responses in cells lacking the known LPA receptors. *FASEB Journal*, **2006**, 20, LB44	0.9	2
62	Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin. *Journal of Medicinal Chemistry*, **2005**, 48, 4919-30	8.3	92
61	Sphingosine 1-phosphate analogue recognition and selectivity at S1P4 within the endothelial differentiation gene family of receptors. *Biochemical Journal*, **2005**, 389, 187-95	3.8	44
60	S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. *Chemistry and Biology*, **2005**, 12, 703-15		212
59	Lysophosphatidic acid inhibits cholera toxin-induced secretory diarrhea through CFTR-dependent protein interactions. *Journal of Experimental Medicine*, **2005**, 202, 975-86	16.6	124
58	Stable knock-down of the sphingosine 1-phosphate receptor S1P1 influences multiple functions of human endothelial cells. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2005**, 25, 546-52	9.4	76
57	Identification of residues responsible for ligand recognition and regioisomeric selectivity of lysophosphatidic acid receptors expressed in mammalian cells. *Journal of Biological Chemistry*, **2005**, 280, 35038-50	5.4	69
56	Lysophosphatidic acid induces neointima formation through PPARgamma activation. *Journal of Experimental Medicine*, **2004**, 199, 763-74	16.6	173
55	Optimal lysophosphatidic acid-induced DNA synthesis and cell migration but not survival require intact autophosphorylation sites of the epidermal growth factor receptor. *Journal of Biological Chemistry*, **2004**, 279, 47871-80	5.4	18
54	Mice with transgenic overexpression of lipid phosphate phosphatase-1 display multiple organotypic deficits without alteration in circulating lysophosphatidate level. *Cellular Signalling*, **2004**, 16, 385-99	4.9	53
53	Thrombogenic and atherogenic activities of lysophosphatidic acid. *Journal of Cellular Biochemistry*, **2004**, 92, 1086-94	4.7	96
52	Lysophospholipids and their G protein-coupled receptors in biology and diseases. *Journal of Cellular Biochemistry*, **2004**, 92, 867-8	4.7	16
51	The plaque lipid lysophosphatidic acid stimulates platelet activation and platelet-monocyte aggregate formation in whole blood: involvement of P2Y1 and P2Y12 receptors. *Blood*, **2004**, 103, 2585-92	2.2	95
50	Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors. *Molecular Pharmacology*, **2003**, 63, 1032-42	4.3	81
49	LPA protects intestinal epithelial cells from apoptosis by inhibiting the mitochondrial pathway. *American Journal of Physiology - Renal Physiology*, **2003**, 284, G821-9	5.1	60

48	Activation of human monocytic cells by lysophosphatidic acid and sphingosine-1-phosphate. *Cellular Signalling*, **2003**, 15, 367-75	4.9	77
47	Inhibition of Ca(2+) signalling by the sphingosine 1-phosphate receptor S1P(1). *Cellular Signalling*, **2003**, 15, 677-87	4.9	22
46	Cyclic phosphatidic acid elicits neurotrophin-like actions in embryonic hippocampal neurons. *Journal of Neurochemistry*, **2003**, 87, 1272-83	6	48
45	Photolysis of intracellular caged sphingosine-1-phosphate causes Ca2+ mobilization independently of G-protein-coupled receptors. *FEBS Letters*, **2003**, 554, 443-9	3.8	79
44	Molecular mechanisms of lysophosphatidic acid action. *Progress in Lipid Research*, **2003**, 42, 498-526	14.3	149
43	Total synthesis of two photoactivatable analogues of the growth-factor-like mediator sphingosine 1-phosphate: differential interaction with protein targets. *Journal of Organic Chemistry*, **2003**, 68, 7046-50	4.2	26
42	Subtype-selective antagonists of lysophosphatidic Acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques. *Circulation*, **2003**, 108, 741-7	16.7	132
41	Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine 1-phosphate generation in blood. *Journal of Biological Chemistry*, **2002**, 277, 21197-206	5.4	197
40	Nerve growth factor signals through TrkA, phosphatidylinositol 3-kinase, and Rac1 to inactivate RhoA during the initiation of neuronal differentiation of PC12 cells. *Journal of Biological Chemistry*, **2002**, 277, 35840-6	5.4	93
39	Injury-elicited differential transcriptional regulation of phospholipid growth factor receptors in the cornea. *American Journal of Physiology - Cell Physiology*, **2002**, 283, C1646-54	5.4	21
38	Lysophosphatidic acid protects and rescues intestinal epithelial cells from radiation- and chemotherapy-induced apoptosis. *Gastroenterology*, **2002**, 123, 206-16	13.3	99
37	Molecular basis for lysophosphatidic acid receptor antagonist selectivity. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2002**, 1582, 309-17	5	69
36	International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. *Pharmacological Reviews*, **2002**, 54, 265-9	22.5	393
35	Plasma lysophosphatidic acid concentration and ovarian cancer. *JAMA - Journal of the American Medical Association*, **2002**, 287, 3081-2	27.4	140
34	Sphingosylphosphocholine is a naturally occurring lipid mediator in blood plasma: a possible role in regulating cardiac function via sphingolipid receptors. *Biochemical Journal*, **2001**, 355, 189-197	3.8	136
33	Synthesis and antitumor properties of a plasmalogen methyl ether analogue. *Tetrahedron*, **2001**, 57, 4277-4282	2.4	6
32	Direct quantitative analysis of lysophosphatidic acid molecular species by stable isotope dilution electrospray ionization liquid chromatography-mass spectrometry. *Analytical Biochemistry*, **2001**, 292, 287-95	3.1	192
31	Physiological responses to lysophosphatidic acid and related glycero-phospholipids. *Prostaglandins and Other Lipid Mediators*, **2001**, 64, 47-62	3.7	78

30	A single amino acid determines lysophospholipid specificity of the S1P1 (EDG1) and LPA1 (EDG2) phospholipid growth factor receptors. *Journal of Biological Chemistry*, **2001**, 276, 49213-20	5.4	85
29	Selective ligands for lysophosphatidic acid receptor subtypes: gaining control over the endothelial differentiation gene family. *Molecular Pharmacology*, **2001**, 60, 1161-4	4.3	23
28	Sphingosylphosphocholine is a naturally occurring lipid mediator in blood plasma: a possible role in regulating cardiac function via sphingolipid receptors. *Biochemical Journal*, **2001**, 355, 189-97	3.8	79
27	Pharmacological characterization of phospholipid growth-factor receptors. *Annals of the New York Academy of Sciences*, **2000**, 905, 34-53	6.5	14
26	Phospholipid growth factors and corneal wound healing. *Annals of the New York Academy of Sciences*, **2000**, 905, 142-58	6.5	28
25	Quantitative analysis of lysophosphatidic acid in human blood fractions. *Annals of the New York Academy of Sciences*, **2000**, 905, 267-9	6.5	31
24	Topical application of LPA accelerates wound healing. *Annals of the New York Academy of Sciences*, **2000**, 905, 270-3	6.5	8
23	Stimulation of platelets and endothelial cells by mildly oxidized LDL proceeds through activation of lysophosphatidic acid receptors and the Rho/Rho-kinase pathway. Inhibition by lovastatin. *Annals of the New York Academy of Sciences*, **2000**, 905, 282-6	6.5	26
22	Characterization of endogenous and heterologously expressed LPA receptor subtypes. *Annals of the New York Academy of Sciences*, **2000**, 905, 287-9	6.5	4
21	A novel lipid mediator, cyclic phosphatidic acid (cPA), and its biological functions. *Annals of the New York Academy of Sciences*, **2000**, 905, 319-21	6.5	12
20	Structural features of EDG1 receptor-ligand complexes revealed by computational modeling and mutagenesis. *Annals of the New York Academy of Sciences*, **2000**, 905, 330-9	6.5	20
19	Sphingosine 1-phosphate as a major bioactive lysophospholipid that is released from platelets and interacts with endothelial cells. *Blood*, **2000**, 96, 3431-3438	2.2	201
18	Lipid phosphate phosphatase-1 and Ca2+ control lysophosphatidate signaling through EDG-2 receptors. *Journal of Biological Chemistry*, **2000**, 275, 27520-30	5.4	31
17	Identification of Edg1 receptor residues that recognize sphingosine 1-phosphate. *Journal of Biological Chemistry*, **2000**, 275, 39379-84	5.4	133
16	Different roles for RhoA during neurite initiation, elongation, and regeneration in PC12 cells. *Journal of Neurochemistry*, **1999**, 73, 949-60	6	99
15	Inactivation of Rho signaling pathway promotes CNS axon regeneration. *Journal of Neuroscience*, **1999**, 19, 7537-47	6.6	523
14	Localization of the PAK1-, WASP-, and IQGAP1-specifying regions of Cdc42. *Journal of Biological Chemistry*, **1999**, 274, 29648-54	5.4	50
13	Edg-2/Vzg-1 couples to the yeast pheromone response pathway selectively in response to lysophosphatidic acid. *Journal of Biological Chemistry*, **1998**, 273, 1506-10	5.4	103

12	Growth factor-like phospholipids generated after corneal injury. *American Journal of Physiology - Cell Physiology*, **1998**, 274, C1065-74	5.4	90
11	Naturally occurring analogs of lysophosphatidic acid elicit different cellular responses through selective activation of multiple receptor subtypes. *Molecular Pharmacology*, **1998**, 54, 979-88	4.3	118
10	Lysophosphatidic acid-induced neurite retraction in PC12 cells: control by phosphoinositide-Ca2+ signaling and Rho. *Journal of Neurochemistry*, **1996**, 66, 537-48	6	170
9	Lysophosphatidic acid-induced neurite retraction in PC12 cells: neurite-protective effects of cyclic AMP signaling. *Journal of Neurochemistry*, **1996**, 66, 549-58	6	111
8	The faciogenital dysplasia gene product FGD1 functions as a Cdc42Hs-specific guanine-nucleotide exchange factor. *Journal of Biological Chemistry*, **1996**, 271, 33169-72	5.4	130
7	The effect of active serum albumin on PC12 cells: II. Intracellular Ca2+ transients and their role in neurite retraction. *Molecular Brain Research*, **1992**, 14, 302-9		27
6	The effect of active serum albumin on PC12 cells: I. Neurite retraction and activation of the phosphoinositide second messenger system. *Molecular Brain Research*, **1992**, 14, 293-301		31
5	Microinjection into Xenopus oocytes: a precise semi-automatic instrument and optimal parameters for injection of mRNAs. *Journal of Proteomics*, **1991**, 22, 243-52		3
4	Modulation of cell-cell and cell-antigen interactions by 1,25-dihydroxyvitamin D3 and vitamin D3 sulfate in vitro: a study on pregnancy lymphocytes and hybridoma cells. *Immunology Letters*, **1989**, 20, 317-22	4.1	
3	Protein structural changes associated with active and inactive states of hydrogenase from Thiocapsa roseopersicina. *Biochimie*, **1986**, 68, 69-74	4.6	11
2	Monoclonal antibodies to the hydrogenase ofThiocapsa roseopersicina. *Current Microbiology*, **1984**, 11, 329-333	2.4	3
1	Isolation of the human myelin basic protein by immunoaffinity chromatography with a monoclonal antibody. *Molecular Immunology*, **1984**, 21, 889-94	4.3	7